27 research outputs found
Método alternativo de avaliação da pressão de preconsolidação por meio de um penetrômetro
Gender and age-related differences in Burkitt lymphoma - epidemiological and clinical data from The Netherlands
Although Burkitt's lymphoma (BL) is classified as one entity in the World Health Organisation (WHO) classification, we wondered whether BL should not be considered as a different disease in children compared with adults. Netherlands Cancer Registry (NCR) data were obtained from 1994 to 1998 (n=203). Detailed clinical data from two treatment protocols were compared: one for adults up to the age of 65 years (n=27) and one for children (n=80). All slides of the two clinical studies were centrally reviewed which included immunophenotyping and when necessary breakpoint analysis of MYC/8q24. Only cases with an unambiguous diagnosis of BL (classical and atypical BL) were accepted. The age distribution of BL-patients showed a bimodal distribution with a peak at the paediatric age and a steady increase after approximately 60 years of age. Most of the patients were males (89% for children and 78% for adults) and only male patients showed this bimodality. Children more often had extranodal disease (81% vs. 59%), whereas adults more often had nodal disease (89% vs. 53%). Based on epidemiology and clinical presentation, the concept that BL is one disease should be re-challenged
Male sexuality after cancer treatment - needs for information and support: testicular cancer compared to malignant lymphoma
Testicular cancer (TC) as well as malignant lymphoma (NIL), both have nowadays an excellent prognosis. However, both types of cancer may be diagnosed at young adulthood and patients may experience sexual concerns. In this article the need for information and support concerning sexuality will be explored, and the traumatic impact of cancer diagnosis with respect to this will be considered. A total of 264 patients with testicular cancer, median age 36 (S.D. 9.7) years, and 50 patients with malignant lymphoma, median age 42 (S.D. 11.7) years returned a questionnaire concerning sexual functioning; four items assessed the need for information or support concerning sexuality, at diagnosis and at follow-up. It appeared that more than half of the patients with testicular cancer reported a lack of information and support concerning sexuality during treatment; 67% of them still had a need for information at follow-up. These rates were significantly lower for patients with malignant lymphoma. Especially patients with testicular cancer who suffered sexual dysfunction reported extremely high needs for information and support. According to these findings it can be concluded that more attention should be paid to the doctor-patient communication with respect to sexual concerns in general, and especially where it concerns patients with testicular cancer. (C) 2003 Published by Elsevier Science Ireland Ltd
Six courses of intensified CHOP plus G-CSF compared to eight courses of standard CHOP in patients with intermediate-risk aggressive non-Hodgkin lymphoma. Results of a prospective randomized HOVON trial
Splenic marginal zone lymphomas presenting with splenomegaly and typical immunophenotype are characterized by allelic loss in 7q31-32
Guideline for diagnosis and treatment of Waldenstrom's macroglobulinaemia.
Item does not contain fulltextOn behalf of the lymphoma and multiple myeloma working parties of the Dutch/Belgian Haemato-Oncology Foundation for Adults in The Netherlands (HOVON), we present a guideline for diagnosis and management of Waldenstrom's macroglobulinemia (WM). Considering the indolent behaviour and heterogeneous clinical presentation of WM, it is crucial to determine the right indications for treatment, as well as to individualise therapeutic options. There are significant differences from the approach to multiple myeloma or the treatment of other indolent non-Hodkgin lymphomas, and these results cannot always be extrapolated. There is a lack of large clinical trials due to the low incidence of WM. Based on the available data, we provide a practical diagnostic classification, as well as recommendations for first-line therapy and options for treating relapsed disease. Some typical clinical features of WM, such as autoimmune phenomena and 'IgM flare' after rituximab treatment, are highlighted. A more elaborate version of this guideline was published in the 'Nederlands Tijdschrift voor Hematologie' (Dutch Journal for Hematology) September 2012.1 maart 201
Intensified 12-week CHOP (I-CHOP) plus G-CSF compared with standard 24-week CHOP (CHOP-21) for patients with intermediate-risk aggressive non-Hodgkin lymphoma: a phase 3 trial of the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON).
Contains fulltext :
53318.pdf (publisher's version ) (Closed access)Optimal dose and timing of CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) chemotherapy for aggressive non-Hodgkin lymphoma (NHL) is still an unresolved issue. We assessed whether dose intensifications with cyclophosphamide and doxorubicin might improve outcome in younger patients with intermediate-risk aggressive NHL. Previously untreated patients were assigned to receive either 8 courses of standard CHOP (n = 239) or 6 courses of intensified (I)-CHOP (n = 238). Although there was a tendency in favor of I-CHOP for overall survival (OS), disease-free survival (DFS), and event-free survival (EFS), the differences were not significant. However, although these analyses were not planned, when the intermediate-risk group was divided into low-intermediate- and high-intermediate-risk patients according to the International Prognostic Index (IPI), low-intermediate-risk patients had improved 6-year OS (67% vs 52%; P = .05), DFS (58% vs 45%; P = .06), and EFS (41% vs 30%; P = .21) when they were treated with I-CHOP compared with standard CHOP. On the other hand, high-intermediate-risk patients seem to have no benefit from I-CHOP. Although clinically relevant side effects occurred more often in the I-CHOP arm, treatment-related mortality was similar. These data suggest that I-CHOP might be preferable to standard CHOP in younger patients with low-intermediate-risk aggressive NHL
Cyclophosphamide and VP 16-213 with autologous bone marrow transplantation. A dose escalation study
Cyclophosphamide and VP 16-213 with autologous bone marrow transplantation. A dose escalation study
U ovom završnom radu daje se uvid u anglizme u govoru mladih. Na početnim stranicama baviti ćemo se samim pojmom jezičnoga posuđivanja, razlozima posuđivanja te tipovima posuđivanja. Nadalje, bit će riječi o podjeli posuđenica prema brojnim kriterijima. Usto, postoje i posebne vrste posuđenica o kojima ćemo također reći nešto više. Nakon toga ćemo se posvetiti anglizmima. Reći ćemo što su anglizmi i dati pojedinosti o njima, te navesti i objasniti njihovu podjelu. Također ćemo navesti primjere najčešće korištenih anglizama. Na kraju rada baviti ćemo se anglizmima u govoru mladih, te navesti primjere popularnih anglizama i akronima.This final paper gives an insight into English language in youth speech. On the first pages, we will deal with the very concept of linguistic borrowing, the reasons for borrowing, and the types of borrowing. Furthermore, there will be a discussion of the division of borrowings according to a number of criteria. In addition, there are special types of borrowings that we will also say more about. After that we will focus on Anglicisms. We will tell what Anglicisms are and give details about it, and list and explain their division. We will also provide examples of commonly used Anglicisms. At the end of the paper, we will deal with Anglicisms in youth speech and give examples of popular Anglicisms and acronyms